Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

April 29, 2024

https://www.globenewswire.com/news-release/2024/04/29/2871345/0/en/Immix-Biopharma-Awarded-European-Union-Orphan-Drug-Designation-for-NXC-201-in-Multiple-Myeloma.html

European Orphan Drug Designation (“ODD”) qualifies NXC-201 for:

LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that the European Commission (EC) has granted orphan drug designation to NXC-201 for the treatment of multiple myeloma.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.